# Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

> **NCT02334527** · PHASE2 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Urothelial Carcinoma (UC)

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT02334527
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-17
- **Primary completion:** 2016-12-02
- **Final completion:** 2017-09-28
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Data from first 12 subjects-primary endpoint not met. Data analysis underway.
- **Last updated:** 2018-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334527, "Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02334527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*